The Department of Defense, through the Defense Health Agency, is seeking innovative solutions for a nanoparticle-based drug delivery platform aimed at treating traumatic brain injury (TBI) in military personnel. The objective is to develop a non-aggregating, brain-targeted nanoparticle system capable of sustained release of neuroprotective drugs to mitigate neuroinflammation, oxidative stress, and edema, which can be safely administered in austere field conditions. This initiative addresses a critical gap in prehospital care for TBI, as there are currently no FDA-approved pharmacological treatments available for effective management of this condition. Interested parties should note that the solicitation is open from September 18, 2024, to October 23, 2024, with further details available at the provided source link.